Crinetics Reports Top-line CRN04894 MAD Results from Phase 1 Study


Crinetics Reports Top-Line Phase 1 MAD results showing CRN04894 suppresses cortisol even in presence of disease-like ACTH concentrations

Crinetics Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update


Crinetics reported financial results for the first quarter 2022 and outlined recent progress, including Phase 1 readout from CRN04777, licensing agreement with SKK, and strengthened management team and balance sheet.

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Crinetics Pharmaceuticals Announces Inducement Grants The stock options were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).

Crinetics Pharmaceuticals Announces Closing of Underwritten Common Stock Offering


Crinetics closed an underwritten public offering of 5,625,563 shares of its common stock, resulting in gross proceeds of approximately $125.0 million.

Crinetics Pharmaceuticals Announces Pricing of Underwritten Common Stock Offering


announced today the pricing of an underwritten follow-on offering of 5,625,563 shares of its common stock at a price to the public of $22.22 per share.